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Pregnancy may increase the risk of adverse maternal and neonatal outcomes in SARS-CoV-2 infection.
Effectiveness of SARS-CoV-2 vaccines in pregnant women is not known. Using a test-negative case-
control study, we determined the vaccine effectiveness of mRNA vaccines in preventing con rmed SARS-
CoV-2 infection in pregnant women at a national referral hospital, which handles > 75% of the deliveries in
Qatar. Among 2,020 pregnant women who met the study criteria, 397 had a positive SARS-CoV-2 RT-PCR
and 1,623 had a negative test. Vaccine effectiveness ≥ 14 days after the second dose was 67.7% (95%CI
30.5–86.9), while vaccine effectiveness ≥ 14 days after the  rst dose but before the second dose was
40.3% (95%CI 0.0-80.4). There were nine severe/critical disease cases, and no deaths in the PCR-positive
pregnant women, all among unvaccinated. The mRNA vaccines provide high level of protection against
documented SARS-CoV-2 infection, which supports including pregnant women in vaccination campaigns.
Introduction
Several vaccines for the SARS-CoV-2 infection have received emergency use authorization across the
globe. The earliest vaccines to obtain such authorization were the BNT-162b2 (P zer) and the mRNA-
1273 (Moderna) vaccines. Early randomized clinical trials using these vaccines reported an e cacy of
94-95% in preventing con rmed SARS-CoV-2 infection or symptomatic COVID-19 disease.1,2 Subsequent
effectiveness studies in the real-world settings have reported similarly high rates of effectiveness in
preventing con rmed infection and nearly 100% effectiveness in preventing severe disease or death.3,4
SARS-CoV-2 infection in pregnant women is often asymptomatic, though maternal infection in pregnancy
is associated with higher rates of neonatal respiratory distress and hospitalization.5,6 However, no
mortality difference in infants born to mothers with SARS-CoV-2 infection in pregnancy has been
observed.6 When maternal infection occurs >60 days prior to delivery, e cient transfer of maternal SARS-
CoV-2 antibodies has been reported with up to 38% of infants demonstrating positive IgG antibodies at
13-28 weeks.7 Despite being at a potentially high risk of more severe disease and adverse outcomes,
pregnant women were excluded from the vaccine e cacy trials.8 Hence, other than very limited data in
women who were inadvertently enrolled in clinical trials, no robust data are available regarding the
effectiveness of SARS-CoV-2 vaccines in pregnant women. We undertook this study to determine the
effectiveness of SARS-CoV-2 mRNA vaccines in pregnant women at a national level in Qatar.
Results
Between December 20, 2020 and May 30, 2021, we identi ed 4,534 with con rmed pregnancy. We
excluded 2,087 without any SARS-CoV-2 testing during the study period and 427 who were tested before
pregnancy onset. (Figure) Among the remaining 2,020 pregnant women, 397 had a positive SARS-CoV-2
RT-PCR and 1,623 had a negative test. For 393 RT-PCR positive pregnant women, we found 1,074
matched RT-PCR negative controls using an algorithm to  nd up to 3 controls for each case. Our  nal
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study groups consisted of 23 vaccinated and 370 unvaccinated cases (“test-positive” group) and 109
vaccinated and 753 unvaccinated controls (“test-negative” group).
The median age was 31 years for the cases and controls. Age group distribution and nationalities of the
cases and controls are presented in table 1. Vaccine effectiveness >14 days after the second dose was
67.7% (95% CI 30.5-86.9), while vaccine effectiveness >14 days after the  rst dose but before the second
dose was 40.3% (95% CI 0.0-80.4). (Table 2)











Median age (IQR) — years 31 (27-34) 31 (28-35) 0.144
Age group — no. (%)      
15-19 years 8 (2.0) 14 (1.6) 0.317
20-24 years 36 (9.2) 96 (11.1)
25-29 years 98 (24.9) 245 (28.4)
30-34 years 137 (34.9) 295 (34.2)
35-39 years 94 (23.9) 159 (18.5)
40-44 years 19 (4.8) 50 (5.8)
45+ years 1 (0.3) 3 (0.3)
Nationality‡      
Bangladeshi 9 (2.3) 9 (1.0) <0.001
Egyptian 39 (9.9) 55 (6.4)
Filipino 26 (6.6) 51 (5.9)
Indian 43 (10.9) 122 (14.2)
Nepalese 0 (0.0) 4 (0.5)
Pakistani 28 (7.1) 40 (4.6)
Qatari  82 (20.9) 272 (31.6)
Sri Lankan 6 (1.5) 8 (0.9)
Sudanese 23 (5.9) 40 (4.6)
Other nationalities§ 137 (34.9) 267 (31.0)
†Cases and controls were matched one-to-five by 5-year age group and reason for polymerase chain reaction (PCR)
testing. 
‡Nationalities were chosen to represent the most populous groups in Qatar.
§These comprise 30 other nationalities in Qatar among Cases, 41 other nationalities among controls.
 
Table 2. Effectiveness of the mRNA Covid-19 vaccines against SARS-CoV-2 infection among








in % (95% CI)
≥14 days after first dose and no second dose
Vaccinated 6 22 40.3 (0.0-80.4)
Unvaccinated 331 724
 
≥14 days after second dose





To our knowledge, this is the  rst large scale study of SARS-CoV-2 vaccine effectiveness in pregnant
women. We found the vaccine effectiveness to be 68.5% in preventing any documented infection.
Pregnant women with SARS-CoV-2 infection are at a higher risk of adverse maternal and neonatal
outcomes. They are more likely to experience premature rupture of membranes, venous thrombotic
events, severe pre-eclampsia, pre-term birth, and fetal death.9,10 Early studies have not shown any
obvious safety issues with the mRNA vaccines in pregnant women,11 while maternal vaccination with the
BNT162b2 vaccine has been shown to induce a robust humoral response in pregnant women with
effective transfer to the fetus.7,12 These data coupled with reasonably high effectiveness in preventing
SARS-CoV-2 infection provides strong rationale for including pregnant women in SARS-CoV-2 vaccination
campaigns using the mRNA vaccines.
While the mRNA vaccines against SARS-CoV-2 infection appear to be safe and effective, equivalent data
for vaccines using other platforms (e.g. adenovirus vector based vaccines, inactivated vaccines) are not
yet available. Urgent clinical trials and real-world safety and effectiveness studies are needed to advocate
use of other vaccines in pregnant women.
Strengths of our study include a large national population of pregnant women, with robust testing and
vaccination data and availability of data on variants of concern. Of all infections diagnosed on these
pregnant women, 74 were alpha variant (previously known as the B1.1.7 variant), 163 were beta variant
(previously known as the B1.351 variant), and 156 were variants of unknown status. Our previous work
has shown that the P zer-BNT162b2 vaccine is 89.5% effective against the alpha variant (previously
known as the B1.1.7 variant) and 75% effective against the beta variants (previously known as the
B1.351 variant).4 The predominant variant in Qatar during the  rst half of the study was the alpha
variant, while beta variant accounted for over 75% of the infections during the second half of the study.
Due to the very small number of outcome events, we were not able to accurately determine vaccine
effectiveness against severe disease and death. However, there were 8 COVID-19 severe disease cases,
one critical disease case, and no deaths in the PCR-positive pregnant women, all of which were among
those unvaccinated and none among those vaccinated. We did not assess the individual effectiveness of
the P zer-BNT162b2 and Moderna-mRNA-1273 vaccines. However, key clinical trials have shown them to
be equally e cacious.1,2
In conclusion, the mRNA vaccines are associated with a 67.7% effectiveness against documented
infection >14 days after the second dose. While lower than the effectiveness observed in non-pregnant
persons, the extremely low number of more severe outcome events among the vaccinated group provides
strong supporting evidence to include pregnant women in SARS-CoV-2 vaccination campaigns.
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Methods
Study Setting and Participants
The study was carried out at Hamad Medical Corporation in Qatar, which provides approximately 85% of
the hospital bed capacity in Qatar. A specialty care hospital for women caters to more than 75% of the
deliveries in Qatar. SARS-CoV-2 vaccination campaign began in Qatar in December 2020, prioritizing high
risk individuals early in the campaign due to limited global supplies of the vaccine. The earliest persons
to be vaccinated included those >70 years old, those with comorbidities, and frontline healthcare workers.
Vaccination was rapidly expanded to younger age groups in a stepwise fashion. Pregnancy itself was not
a priority condition, though pregnant women were encouraged to get vaccinated based on age and
comorbidity criteria.
All women who presented to Hamad Medical Corporation between December 20, 2020 and May 30, 2021
with con rmed pregnancy were eligible to be included for the current study. Pregnant women were
identi ed from the centralized hospital electronic medical records. Pregnancy was ascertained by
presence of diagnostic codes for pregnancy in women attending antenatal clinics. We excluded those
who were tested for SARS-CoV-2 by RT-PCR on a nasopharyngeal swab prior to pregnancy and those who
had no SARS-CoV-2 testing done between December 20, 2020 and May 30, 2021. For each woman who
tested among the vaccinated group, we identi ed up to 3 RT-PCR negative controls matched on age and
reason for testing.
Statistical Analyses
We used test-negative case control design to determine the effectiveness of vaccination against
con rmed SARS-CoV-2 infection. This design is a widely accepted standard to determine vaccine
effectiveness in a population after the introduction of a vaccine.13-15 Vaccine effectiveness was
determined using the following formula:
The test-negative design is predicated on negative controls getting tested for symptoms compatible with
the outcome of intertest (in this case, SARS-CoV-2 infection). In a real-world setting, those getting tested
for a speci c disease or infection approximate this population and the above formula can be applied.13
We have used the same design to report overall effectiveness of the P zer-BNT162b2 vaccine against the




We determined overall vaccine effectiveness >14 days after the second dose of the vaccine as our
primary outcome of interest. We also determined vaccine effectiveness >14 days after the  rst dose up to
the date of the second dose. For all point estimates of vaccine effectiveness, we calculated the
corresponding 95% con dence intervals.16,17
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Figure 1
Flowchart of dataset creation.
Supplementary Files
This is a list of supplementary  les associated with this preprint. Click to download.
Supplementarymaterials.docx
 atButtepc.pdf
